Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Prognostic significance of PET-CT status after first line immuno-chemotherapy for FL

Judith Trotman • 25 Jun 2020
EHA 2020
Follicular Lymphoma Lymphoma Antibodies Bendamustine Obinutuzumab Rituximab
GALLIUM

Judith Trotman, MBChB, FRACP, FRCPA, of the University of Sydney School of Medicine, Sydney, Australia, discusses the prognostic value of PET-CT status after long-term follow-up of follicular lymphoma (FL) patients enrolled in the GALLIUM study (NCT01332968) which aimed to evaluate the efficacy of first-line immunochemotherapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Judith Trotman

4:20
Lymphoma during the COVID-19 pandemic
Judith Trotman • 20 May 2020
3:48
Impressive data: zanubrutinib for Waldenström’s macroglobulinemia
Judith Trotman • 26 May 2020

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals